Filing Flows › Companies › Novo Nordisk A S › Timeline
Novo Nordisk A S stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−9.1% to $40.31
Novo Nordisk A S (NVO) stock fell 9% over the last 252 sessions, to $40.31. On the way it reported 4 quarters, its insiders filed no open-market trades (10b5-1 plan sales aside), and the company filed 0 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 4, 2026 | Earnings | Earnings: beat the EPS estimate by 25.3% | +4.8% (+3.2% vs SPY) | — | — |
| Aug 4, 2026 | Earnings | Earnings: beat the EPS estimate by 24.0% | −6.1% (−7.9% vs SPY) | +1.4% (−0.7% vs SPY) | −3.0% (−3.6% vs SPY) |
| May 6, 2026 | Earnings | Earnings: missed the EPS estimate by -4.8% | +2.0% (+0.6% vs SPY) | +4.6% (+2.7% vs SPY) | −2.5% (−7.0% vs SPY) |
| Feb 3, 2026 | Earnings | Earnings: beat the EPS estimate by 2.3% | −15.8% (−15.0% vs SPY) | −17.7% (−17.5% vs SPY) | −42.6% (−41.1% vs SPY) |
Report card: every quarter against the estimate → Novo Nordisk A S: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.